BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer

MT Newswires Live

昨天

BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.

The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.

Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.

Gotistobart's safety profile "remained manageable" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.

BioNTech shares were up 2.9% in Monday premarket activity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2667651466"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667651466\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667651466?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667651466","market":"sh","top_or_hot":-1,"title":"BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer","media":"MT Newswires Live","content":"<html><body><p> BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.</p><p>The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.</p><p>Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.</p><p>Gotistobart's safety profile \"remained manageable\" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.</p><p>BioNTech shares were up 2.9% in Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-14 17:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.</p><p>The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.</p><p>Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.</p><p>Gotistobart's safety profile \"remained manageable\" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.</p><p>BioNTech shares were up 2.9% in Monday premarket activity.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667651466","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667651466","pubTimestamp":1789376674,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patient","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4551":"寇图资本持仓","BNTX":"BioNTech SE","BK4588":"碎股","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"translate_title":"BioNTech 和 OncoC4 报告 Gotistobart 治疗肺癌 3 期试验的积极总生存率数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"BioNTech (BNTX) and OncoC4 said Monday that updated data from the first stage of their phase 3 PRESERVE-003 trial showed a statistically significant overall survival benefit for gotistobart in patients previously treated with squamous non-small cell lung cancer.The company said data showed that gotistobart nearly doubled overall survival compared with standard-of-care chemotherapy in 87 patients in the trial.Median overall survival was 18.5 months for patients treated with gotistobart compared with 10 months for those receiving standard-of-care docetaxel chemotherapy, according to the statement.Gotistobart's safety profile \"remained manageable\" and consistent with previously reported data, the partners added. The companies said about 44 out of every 100 patients taking gotistobart experienced a serious side effect related to the treatment, compared with about 49 out of every 100 patients taking docetaxel.BioNTech shares were up 2.9% in Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}